trial

Pharmacogenetic Supported Prescribing in Kids

NCTId NCT04797364
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Active Not Recruiting
Enrollment 6,000 (estimated)
Sponsored by University of Calgary
Primary completion 2026-10-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Active Not Recruiting
Enrollment
6,000 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-01-18
Primary completion
2026-10-01
Eligibility
ALL · 6 Years · 24 Years

Interventions & indications

Drugs
Pharmacogenetic Testing

Sponsors

University of CalgaryLead Sponsor

Investigators

1
Chad Bousman, PhDPrincipal Investigator

Sites

1 total
Calgary, Canada

Facts & assertions

4 sourced
Enrollment
6,000
Phase
NA
Primary Completion Date
2026-10-01
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Pharmacogenetic Testing
drug
lead_sponsor
University of Calgary
company
indication
Mental Health Impairment
indication
Bipolar Disorder
indication
Psychotic Disorders
indication
investigator
Chad Bousman, PhD
person